Benhamou Research Group

Our laboratory develops chemical strategies to modulate disease-associated RNA complexes, integrating chemical biology, medicinal chemistry, molecular and cellular biology, and computational approaches. Our research spans small molecules, antisense oligonucleotides, and heterobifunctional chimeras designed to interrogate biological mechanisms and correct disease-driving processes. A central focus is induced proximity: designing molecules that recruit endogenous cellular machinery to control the abundance, activity, and subcellular localization of pathogenic targets. We seek to overcome limitations of conventional inhibition and expand the range of therapeutically accessible RNA and RNA-binding protein complexes. Complementing these efforts, we develop antisense approaches to modulate RNA expression, translation, and regulatory interactions. Our work also extends to membrane proteins, demonstrating their susceptibility to targeted degradation and exploring new opportunities for therapeutic intervention. We integrate computational approaches with experimental discovery to guide molecular design, prioritize candidates, and investigate the structural determinants of target recognition and selective modulation. Across cancer, genetic and metabolic disorders, neurological diseases, and infectious diseases, our goal is to generate mechanistically defined chemical probes and therapeutic candidates that translate molecular insights into innovative treatment strategies.​